The Company Perspective: Maximizing the Value of Intellectual Property and Strategic Collaborations
Event | 04.25.17, 4:00 PM UTC - 6:30 PM UTC
Address
Institute for Bioscience & Biotechnology Research
9600 Gudelsky Drive, Rockville, MD 20850
BDO and Crowell & Moring are proud to present a networking opportunity and a panel discussion on IP Strategy for the BioPharma Industry. This is a "must attend" event for hearing and discussing the company perspective from companies engaged in drug, vaccine, biologic, or medical device research and product development. IP and the strategy to procure and sustain it is one of the most critical aspects to revenue generation and commercial success. Our panel members are admired veterans in this field and will present intriguing case studies that will emphasize lessons learned and practical solutions to creating a successful IP strategy.
AGENDA
4:00 pm - Registration & Networking
4:15 pm - Introduction by Tom Fuchs, Managing Director, GovCon Speciality Services, BDO USA LLP
4:15 - 5:30 pm - Panel Discussion, Q&A
"News & Evolving IP Changes & Collaborations Impacting the Landscape"
- Moderator: Bryan Brewer, Partner and Co-chair, Corporate, Crowell & Moring
- Terry Rea, Partner, Intellectual Property, Crowell & Moring
- Michelle Wales, Ph.D., J.D., Principal, InHouse Patent Counsel, LLC
- Debra Bowes, EVP Business & Strategic Development, MaxCyte
- Jim Kastenmayer, Senior Patent Director, AstraZeneca
5:30 pm - Appetizers, Refreshments & Networking
For more information, please visit these areas: Intellectual Property, Intellectual Property Litigation
Participants
Insights
Event | 02.20.25
Has the Buss Stopped? Recoupment Today
Has the Buss Stopped? Recoupment Today: In 1997, the California Supreme Court decided Buss v. Superior Court. In Buss, the court concluded that a liability insurer that defended a mixed action could seek reimbursement from the insured for the defense costs associated with the claims that were not even potentially covered. Since then, numerous courts have held that insurers are entitled to recoup their defense costs associated with uncovered claims or causes of action. On the other hand, a significant number of courts have rejected insurers’ right to recoupment, at least in the absence of a policy provision granting the insurer that right. Some commentators have even suggested that the current judicial trend might be away from permitting insurers to recoup their defense costs. Is that correct? Has the Buss stopped? This panel of coverage experts will analyze insurers’ claimed right to recoupment today, and offer their perspectives on what the law on recoupment should perhaps be and might be in the future.
Event | 12.05.24
Event | 12.03.24
